Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645202 | 1.00 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6645133 | 0.94 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6645138 | 0.94 | CCR5 (0.72) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6093438 | 0.89 | CCR5 (0.77) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6093448 | 0.89 | CCR5 (0.77) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6649822 | 0.88 | CCR5 (0.74) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6649818 | 0.88 | CCR5 (0.74) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6648581 | 0.88 | CCR5 (0.76) | CCR5KCNH2CYP2D6 | |
| SCHEMBL6648578 | 0.88 | CCR5 (0.76) | CCR5KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6759158 | 0.85 | CCR5 (0.71) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1448525-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042178-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CX3CR1 | CCR5 1/4885KCNH2 2886/4885CYP2D6 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.